公开(公告)号：US20220389101A1

公开(公告)日：2022-12-08

申请号：US17739940

申请日：2022-05-09

Applicant: GENMAB A/S

Inventor： Rik RADEMAKER ,  Isil ALTINTAS ,  Patrick ENGELBERTS ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/32

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20210317225A1

公开(公告)日：2021-10-14

申请号：US17345628

申请日：2021-06-11

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20210163616A1

公开(公告)日：2021-06-03

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20210070877A1

公开(公告)日：2021-03-11

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200247899A1

公开(公告)日：2020-08-06

申请号：US16855703

申请日：2020-04-22

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20200239579A1

公开(公告)日：2020-07-30

申请号：US16491464

申请日：2018-03-09

Applicant: GENMAB A/S

Inventor： Isil ALTINTAS ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rik RADEMAKER ,  Paul PARREN ,  Bart DE GOEIJ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.